Biological properties of hypoxia-related gene expression models/signatures on clinical benefit of anti-EGFR treatment in two head and neck cancer window-of-opportunity trials
Oral Oncol. 2022 Mar:126:105756.
doi: 10.1016/j.oraloncology.2022.105756.
Epub 2022 Feb 2.
1 Integrated Biology Platform, Department of Applied Research and Technology Development, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
2 Head and Neck Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy; Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy.
3 Head and Neck Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
4 Cancer Center, Department of Medical Oncology, Cliniques universitaires Saint-Luc and Institut de Recherche Clinique et Expérimentale (Pole MIRO), Université Catholique de Louvain, Brussels, Belgium; Department of Head and Neck Surgery, Cliniques universitaires Saint-Luc, Brussels, Belgium.
5 Department of Head and Neck Surgery, Cliniques universitaires Saint-Luc, Brussels, Belgium; Department of Medical Oncology, Institut Roi Albert II, Cliniques universitaires Saint-Luc, Brussels, Belgium; Institut de Recherche Clinique et Experimentale, Université Catholique de Louvain (UCLouvain), Brussels, Belgium.
6 Integrated Biology Platform, Department of Applied Research and Technology Development, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy. Electronic address: loris.dececco@istitutotumori.mi.it.